{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"5.5","value":"1.45"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"5.8","value":"2.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Time to response was defined as the time from randomization to confirmed response (complete response or partial response).","dispersionType":"Full Range","groups":[{"description":"Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).","id":"OG000","title":"Vemurafenib"},{"description":"Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants randomized by September 22, 2010 and with a best overall confirmed response of complete response or partial response.","reportingStatus":"POSTED","timeFrame":"From randomization (initiated January 2010) until December 30, 2010.","title":"Time to Confirmed Response","type":"SECONDARY","unitOfMeasure":"months"}